<Disease><Name>NARP SYNDROME</Name><Synonym>NEUROPATHY, ATAXIA, AND RETINITIS PIGMENTOSA</Synonym><OMIM><Number>551500</Number><URL>http://omim.org/entry/551500</URL></OMIM><Orphanet><Number>644</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=644</URL></Orphanet><Protein><Number /><URL /></Protein><ExPASy><Number /><URL /></ExPASy><Gene>unkwown</Gene><ICD>G31.8</ICD><Summary>rare;mitochondrial inheritance;mutations in the mitochondrial ATP synthase 6 gene</Summary><Symptoms><symtomp><id>3210</id><symptom>apnea</symptom><category>LUNG OR RESPIRATORY SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>1942</id><symptom>ataxia</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2211</id><symptom>blindness, visual loss, visual impairment</symptom><category>EYES | NERVOUS SYSTEM</category></symtomp><symtomp><id>3165</id><symptom>dementia</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>3819</id><symptom>developmental delay</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2423</id><symptom>early death</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2256</id><symptom>EMG abnormalities [-]</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>2105</id><symptom>encephalopathy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>3709</id><symptom>epilepsy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2433</id><symptom>hearing defect, deafness</symptom><category>EARS | NERVOUS SYSTEM</category></symtomp><symtomp><id>3381</id><symptom>learning disability</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>3351</id><symptom>leukoencephalopathy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2424</id><symptom>mental retardation</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1787</id><symptom>muscle weakness</symptom><category>MUSCLES</category></symtomp><symtomp><id>3369</id><symptom>neuropathy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1723</id><symptom>nystagmus</symptom><category>EYES | NERVOUS SYSTEM</category></symtomp><symtomp><id>2506</id><symptom>onset, adolescent / adolescence</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1915</id><symptom>onset, adulthood / adoulthood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1939</id><symptom>peripheral neuropathy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>3629</id><symptom>proteinuria</symptom><category>GENITOURINARY TRACT</category></symtomp><symtomp><id>1958</id><symptom>psychosis</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2461</id><symptom>renal failure, acute/chronic</symptom><category>GENITOURINARY TRACT</category></symtomp><symtomp><id>1731</id><symptom>retinitis pigmentosa</symptom><category>EYES</category></symtomp><symtomp><id>2375</id><symptom>retinopathy</symptom><category>EYES</category></symtomp><symtomp><id>1943</id><symptom>seizures</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>2109</id><symptom>short stature</symptom><category>GENERAL TOPICS</category></symtomp></Symptoms><Metabolites><metabolite><id>1940</id><name>Citrulline</name><specimen>plasma</specimen><value>normal/dec</value><min>8.00</min><max>47.00</max><unit>&#956;mol/l</unit><age>Childhood</age><method>HPLC</method><comment /></metabolite><metabolite><id>17</id><name>Citrulline</name><specimen>urine</specimen><value>normal/dec</value><min>0.00</min><max>9.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>864</id><name>Citrulline</name><specimen>urine</specimen><value>normal/dec</value><min>0.00</min><max>10.00</max><unit>mmol/mol creatinine</unit><age>Childhood</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1759</id><name>Citrulline</name><specimen>urine</specimen><value>normal/dec</value><min>0.00</min><max>780.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>? Maximum 790 ?</comment></metabolite><metabolite><id>1899</id><name>Citrulline</name><specimen>urine</specimen><value>normal/dec</value><min>0.00</min><max>9.00</max><unit>mmol/mol creatinine</unit><age>Infancy</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1900</id><name>Citrulline</name><specimen>urine</specimen><value>normal/dec</value><min>0.00</min><max>9.00</max><unit>mmol/mol creatinine</unit><age>Adolescence</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1901</id><name>Citrulline</name><specimen>urine</specimen><value>normal/dec</value><min>0.00</min><max>9.00</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>16</id><name>Citrulline</name><specimen>plasma</specimen><value>normal/dec</value><min>7.00</min><max>50.00</max><unit>&#956;mol/l</unit><age>Neonatal</age><method>HPLC</method><comment /></metabolite><metabolite><id>1189</id><name>Citrulline</name><specimen>plasma</specimen><value>normal/dec</value><min>15.00</min><max>55.00</max><unit>&#956;mol/l</unit><age>Adulthood</age><method>HPLC</method><comment /></metabolite><metabolite><id>1292</id><name>Citrulline</name><specimen>plasma</specimen><value>normal/dec</value><min>7.00</min><max>35.00</max><unit>&#956;mol/l</unit><age>Infancy</age><method>HPLC</method><comment /></metabolite><metabolite><id>1293</id><name>Citrulline</name><specimen>plasma</specimen><value>normal/dec</value><min>19.00</min><max>52.00</max><unit>&#956;mol/ml</unit><age>Adolescence</age><method>HPLC</method><comment /></metabolite></Metabolites><Literatures><literature><id>6640</id><title>Renal Involvement in Neuropathy, Ataxia, Retinitis Pigmentosa (NARP) Syndrome: A Case Report</title><author>Lemoine S,</author><journal>Am J Kidney Dis</journal><year>2018</year><book /><volume>71</volume><number>5</number><pages>754-757</pages><co_aut>et al.</co_aut></literature><literature><id>6641</id><title>A 2 bp deletion in the mitochondrial ATP 6 gene responsible for the NARP (neuropathy, ataxia, and retinitis pigmentosa) syndrom</title><author>Mordel P,</author><journal>Biochem Biophys Res Commun</journal><year>2017</year><book /><volume>494</volume><number>1</number><pages>133-137</pages><co_aut>et al.</co_aut></literature><literature><id>6642</id><title>Mitochondrial DNA-Associated Leigh Syndrome and NARP</title><author>Thorburn DR,</author><journal>Source  GeneReviews&#174; [Internet]</journal><year>2017</year><book /><volume>0</volume><number>0</number><pages /><co_aut>Rahman J, Rahman S</co_aut></literature><literature><id>5276</id><title>Low dose clozapine controls adult-onset psychosis associated with the neurogenic ataxia-retinitis pigmentosa (NARP) mutation</title><author>Demily C,</author><journal>Mol Genet Metab Rep</journal><year>2016</year><book /><volume>10</volume><number>0</number><pages>20-22</pages><co_aut>et al.</co_aut></literature><literature><id>5277</id><title>Novel genetic and neuropathological insights in neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP)</title><author>Claeys KG,</author><journal>Muscle Nerve</journal><year>2016</year><book /><volume>54</volume><number>2</number><pages>328-333</pages><co_aut>et al.</co_aut></literature><literature><id>5278</id><title>Expanding the clinical phenotypes of MT-ATP6 mutations</title><author>Lopez-Gallardo E,</author><journal>Hum Mol Genet</journal><year>2014</year><book /><volume>23</volume><number>23</number><pages>6191-6200</pages><co_aut>et al.</co_aut></literature><literature><id>5279</id><title>NARP Syndrome: A 20-Year Follow-Up</title><author>Rawle MJ,</author><journal>Case Rep Neurol</journal><year>2013</year><book /><volume>5</volume><number>3</number><pages>204-207</pages><co_aut>Larner AJ</co_aut></literature><literature><id>5280</id><title>Identification and biochemical characterization of the novel mutation m.8839G</title><author>Blanco-Grau A,</author><journal>Genes Brain Behav</journal><year>2013</year><book /><volume>12</volume><number>8</number><pages>812-820</pages><co_aut>et al.</co_aut></literature><literature><id>5281</id><title>A novel mitochondrial mutation m.8989G</title><author>Duno M,</author><journal>Gene</journal><year>2013</year><book /><volume>515</volume><number>2</number><pages>372-375</pages><co_aut>et al.</co_aut></literature><literature><id>5282</id><title>Posterior leukoencephalopathy in NARP syndrome</title><author>Renard D,</author><journal>Acta Neurol Belg</journal><year>2012</year><book /><volume>112</volume><number>4</number><pages>417-418</pages><co_aut>Labauge P</co_aut></literature><literature><id>2213</id><title>The mtDNA T8993G (NARP) mutation results in an impairment of oxidative phosphorylation that can be improved by antioxidants</title><author>Mattiazzi M</author><journal>Hum Mol Genet</journal><year>2004</year><book /><volume>13</volume><number>8</number><pages>869-879</pages><co_aut>et al.</co_aut></literature><literature><id>1034</id><title>The neurogenic weakness, ataxia and retinitis pigmentosa (NARP) syndrome mtDNA mutation (T8993G) triggers muscle ATPase deficien</title><author>Parfait B</author><journal>Eur J Pediatr</journal><year>1999</year><book /><volume>158</volume><number>1</number><pages>55-58</pages><co_aut>et al.</co_aut></literature><literature><id>1035</id><title>Persistent hypocitrullinaemia as a marker for mtDNA NARP T 8993 G mutation?</title><author>Rabier D</author><journal>J Inherit Metab Dis</journal><year>1998</year><book /><volume>21</volume><number>0</number><pages>216-219</pages><co_aut>et al.</co_aut></literature><literature><id>1036</id><title>Polysomnographic findings in a patient with the mitochondrial encephalomyopathy NARP</title><author>Sembrano E</author><journal>Neurology</journal><year>1997</year><book /><volume>49</volume><number>0</number><pages>1714-1717</pages><co_aut>et al.</co_aut></literature><literature><id>1037</id><title>Heterogeneous clinical presentation of the mtDNA NARP/T8993G mutation</title><author>Santorelli FM</author><journal>Neurology</journal><year>1997</year><book /><volume>49</volume><number>0</number><pages>270-273</pages><co_aut>et al.</co_aut></literature><literature><id>1038</id><title>Correlation between the clinical symptoms and the proportion of mitochondrial DNA carrying the 8993 point mutation in the NARP s</title><author>Makela-Bengs P</author><journal>Pediatr Res</journal><year>1995</year><book /><volume>37</volume><number>0</number><pages>634-639</pages><co_aut>et al.</co_aut></literature><literature><id>1040</id><title>The mitochondrial DNA mutation at 8993 associated with NARP slows the rate of ATP synthesis in isolated lymphoblasts mitochondri</title><author>Tatuch Y</author><journal>Biochem Biophys Res Commun</journal><year>1993</year><book /><volume>92</volume><number>0</number><pages>124-128</pages><co_aut>Robinson BH</co_aut></literature><literature><id>1033</id><title>A new mitochondrial disease associated with mitochondrial DNA heteroplasmy</title><author>Holt IJ</author><journal>Am J Hum Genet</journal><year>1990</year><book /><volume>46</volume><number>0</number><pages>428-433</pages><co_aut>et al.</co_aut></literature></Literatures></Disease>